p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation
1998

p53 Mutation and Survival in Liver Cancer

Sample size: 42 publication Evidence: moderate

Author Information

Author(s): K Honda, E Sbisa, A Tullio, PA Papeo, C Saccone, S Poole, M Pignatelli, RR Mitry, S Ding, A Isla, A Davies, NA Habib

Primary Institution: Hammersmith Hospital, RPMS, London, UK

Hypothesis

Does p53 mutation influence survival in hepatocellular carcinoma patients undergoing surgical resection?

Conclusion

p53 mutations are associated with significantly poorer survival in patients with hepatocellular carcinoma after surgery.

Supporting Evidence

  • Patients with wild-type p53 had a mean survival of 60 months, while those with mutations had a mean survival of only 15 months.
  • Eight of 12 HCCs with cirrhosis due to viral hepatitis displayed p53 mutations.
  • The study identified novel mutations in codons 136 and 213 of the p53 gene.

Takeaway

This study found that patients with liver cancer who have p53 mutations tend to live for a shorter time after surgery compared to those without these mutations.

Methodology

The study analyzed tumor samples from 42 patients for p53 mutations using various genetic techniques and compared survival rates based on mutation status.

Limitations

The study focused only on a specific group of patients and may not be generalizable to all liver cancer patients.

Participant Demographics

14 women and 28 men with a mean age of 54.6 years.

Statistical Information

P-Value

0.003

Statistical Significance

p=0.003

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication